(Total Views: 525)
Posted On: 02/25/2025 8:59:42 PM
Post# of 154593
As stated, Oct. 28, 2022:
"CytoDyn plans to publish soon the safety and efficacy data in which it met its primary endpoint, in its Phase 2b/3 randomized, double-blinded, placebo-controlled trial for the HIV-MDR population, in a peer-reviewed journal.
*MDR was published about a week or so ago.
"For example, the Company plans to continue to pursue other underserved HIV-related indications, where it can potentially be first to market."
*Dr. Sacha's multiple Hiv projects.
*BG/ViiV(GSK).
*Hiring of Max.
*GF $1m grant to Dr. Sacha days ago.
The press release is a good re-read.
cytodyn.com/newsroom/press-...
"CytoDyn plans to publish soon the safety and efficacy data in which it met its primary endpoint, in its Phase 2b/3 randomized, double-blinded, placebo-controlled trial for the HIV-MDR population, in a peer-reviewed journal.
*MDR was published about a week or so ago.
"For example, the Company plans to continue to pursue other underserved HIV-related indications, where it can potentially be first to market."
*Dr. Sacha's multiple Hiv projects.
*BG/ViiV(GSK).
*Hiring of Max.
*GF $1m grant to Dr. Sacha days ago.
The press release is a good re-read.
cytodyn.com/newsroom/press-...
(7)
(0)
